{
    "clinical_study": {
        "@rank": "55369", 
        "arm_group": [
            {
                "arm_group_label": "THS 2.2", 
                "arm_group_type": "Experimental", 
                "description": "Ad libitum use of THS 2.2"
            }, 
            {
                "arm_group_label": "Smoking abstinence (SA)", 
                "arm_group_type": "Sham Comparator", 
                "description": "Abstinence from smoking"
            }, 
            {
                "arm_group_label": "Conventional Cigarettes (CC)", 
                "arm_group_type": "Active Comparator", 
                "description": "Ad libitum use of Conventional Cigarettes."
            }
        ], 
        "brief_summary": {
            "textblock": "The overall goal of the study is to evaluate if the ad libitum use of the THS 2.2 for 5 days\n      by adult healthy smokers results in a reduction in the levels of biomarkers of exposure for\n      selected harmful and potentially harmful constituents (HPHCs) compared to smoking\n      conventional cigarettes and smoking abstinence."
        }, 
        "brief_title": "Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in Confinement", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Subject is Caucasian.\n\n          -  Smoking, healthy subject as judged by the Investigator.\n\n          -  Subject smokes at least 10 commercially available non-menthol CCs per day (no brand\n             restrictions) for the last 4 weeks, based on self-reporting.\n\n          -  Subject has smoked for at least the last 3 consecutive years.\n\n          -  Subject does not plan to quit smoking in the next 3 months.\n\n        Exclusion Criteria\n\n          -  As per Investigator judgment, the subject cannot participate in the study for any\n             reason (e.g., medical, psychiatric, and/or social reason).\n\n          -  The subject has received medication within 14 days or within 5 half-lives of the\n             medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2)\n             or cytochrome P450 2A6 (CYP2A6) activity.\n\n          -  For women: Subject is pregnant or is breast feeding.\n\n          -  For women: Subject does not agree to use an acceptable method of effective\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "169", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959932", 
            "org_study_id": "ZRHR-REXC-03-EU", 
            "secondary_id": "ZRHR-REXC-03-EU"
        }, 
        "intervention": [
            {
                "arm_group_label": "THS 2.2", 
                "description": "THS 2.2 ad libitum for 5 days in confinement", 
                "intervention_name": "THS 2.2", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Smoking abstinence (SA)", 
                "description": "SA for 5 days in confinement", 
                "intervention_name": "SA", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Conventional Cigarettes (CC)", 
                "description": "Subject's own preferred brand of CC ad libitum for 5 days in confinement", 
                "intervention_name": "CC", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking", 
            "Modified Risk Tobacco Product", 
            "Conventional cigarettes", 
            "Reduced exposure", 
            "Confinement"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kajetany", 
                    "country": "Poland", 
                    "zip": "05-830"
                }, 
                "name": "BioVirtus Research Site Sp. z o.o."
            }
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Controlled, Open-label, 3-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smoking, Healthy Subjects Switching to the THS 2.2 or Smoking Abstinence, Compared to Continuing to Use Conventional Cigarettes, for 5 Days in Confinement", 
        "overall_official": [
            {
                "affiliation": "BioVirtus Research Site", 
                "last_name": "Katarzyna Jarus-Dziedzic, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Philip Morris Products S.A.", 
                "last_name": "Christelle Haziza, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: Bioethics Committee, The District Chamber of Physicians in Warsaw", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Measurement of  the reduction of exposure to HPHCs: respectively 1,3-butadiene; acrolein; benzene and carbon monoxide (HPHCs) after 5 days of switching from conventional cigarettes to THS 2.2 compared to values measured in subjects who continue smoking conventional cigarettes.", 
            "measure": "Measurement of BOExp to HPHCs: monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA);  S-phenylmercapturic acid (S-PMA)  as concentration adjusted to creatinine in urine and carboxyhemoglobin (COHb) in blood as %", 
            "safety_issue": "No", 
            "time_frame": "Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959932"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philip Morris Products S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philip Morris Products S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}